医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

A Technology Project of Beijing Handian Pharmaceutical: Honee Taishen Granule for COVID-19

2020年06月28日 PM12:18
このエントリーをはてなブックマークに追加


 

BEIJING

The research team of Handian Pharmaceutical Medical Center and Handian Traditional Chinese Medicine Hospital has devoted to develop a new formula against COVID-19, which in traditional Chinese medicine theory, is differentiated as cold-dampness viral disease with the symptoms of fever, aversion to cold, cough, fatigue, general aching pain, headache, diarrhea, etc. After several months of hardworking, they initially developed Honee Taishen Granule (also known as Handian HD1). Cooperating with Chinese Academy of Medical Sciences and Good Laboratory Practice (GLP) certification agencies, Handian Pharmaceutical Medical Center has completed pharmacy studies. Pharmacology and toxicology tests are still in progress to further evaluate its safety and efficacy.

This formula is derived from a famous traditional Chinese medicine prescription. Its components can eliminate dampness and turbidity, repel foulness and remove toxin, which give it cold-dampness eliminating and antiviral effects. According to traditional Chinese medicine theory, it rectifies taiyin cold damp constitution and restores yin-yang balance of the body, which can help patients regain immunity and prevents the virus from affecting the spleen (pancreas) to damage the body.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200627005012/en/

CONTACT

For more information, please contact:

Xiaoteng Bai

Branding and strategy Manager

Beijing Handian Science & Technology (Group) Co., Ltd.

Email: Baixiaoteng@handian.com

Phone: +86 010 5690 3502

Website: http://www.hantien.com.cn/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 亚马逊与美国国家安全委员会携手开展业界首创合作项目,以解决美国常见的工伤问题
  • Aragen Announce Multi-Year Partnership With FMC Corporation, Aims at Accelerating Agro-Chemical Pipeline
  • 片肺換気中の高酸素血症介在疾患の罹患率にORiを指針とする酸素需要評価が及ぼす影響についての新研究
  • セルトリオン、抗COVID-19モノクローナル抗体治療剤「Regdanvimab(CT-P59)」の グローバル第3相臨床試験結果を発表
  • 沃特世推出SELECT SERIES MRT多反射飞行时间质谱平台,树立高分辨质谱性能新标杆